Multi Omics Data Integration to predict the M. tuberculosis Bedaquiline Resistance Phenotype from the Genotype
A 7-laboratory study to calibrate antimicrobial susceptibility testing methods and breakpoints against EUCAST reference standards for bedaquiline, clofazimine, levofloxacin, and linezolid
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors (RespiriTB).
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors (RespiriTB).
Progress novel assets (one FIH start) for nontubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs (RespiriNTM).
Protocol, rationale and design of BE-PEOPLE (Bedaquiline enhanced exposure prophylaxis for LEprosy in the Comoros): a cluster randomized trial on effectiveness of rifampicin and bedaquiline as post-exposure prophylaxis of leprosy contacts
Validation of bedaquiline phenotypic drug susceptibility testing methods and breakpoints: a multilaboratory, multicountry study
Linking in vitro intrinsic dissolution rate and thermodynamic solubility with pharmacokinetic profiles of bedaquiline long-acting aqueous microsuspensions in rats
A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant